CNP Assurances is pursuing its commitment as a sponsor of Fondation pour la Recherche Médicale (FRM, a medical research foundation) with funding of €596k over three years (2024-2026) for an innovative new research project on Alzheimer’s disease.
As part of its “Acting on Neurodegeneration” programme, FRM supports research projects aimed at better understanding the mechanisms behind the emergence of neurodegenerative diseases with a view to prevention, early diagnosis and treatment. Combating neurodegeneration is a top priority for FRM.
Among these projects, CNP Assurances has chosen one intended to “Understand the links between the development of the pathology and metabolic abnormalities” and will contribute to its funding through a donation of €596k over a three-year period (2024-2026). Led by an interdisciplinary research consortium headed by Erika Cecon, CNRS Research Officer at the Cochin Institute in Paris, the project explores avenues to improve defective metabolic functions and thus open a new path for therapeutic research on Alzheimer’s. New studies suggest that this pathology is characterised not just by neurological problems but also by metabolism malfunction (breathing, circulation, digestion, etc.).
CNP Assurances is thus demonstrating its professional and societal commitment to the important issue of neurodegenerative diseases, directly linked to its long-standing efforts on dependency issues.
By selecting the best scientific projects in all fields, FRM is seeking to boost research on understanding the mechanisms of neurodegenerative diseases and foster innovative research based on an interdisciplinary approach, the aim being to open up new diagnosis and therapy pathways likely to apply in concrete terms to these diseases.
“Given the societal issues caused by an ageing population, more than ever before our role as a responsible insurer is to protect people and everything they value over the long term. The sponsorship of CNP Assurances expresses this engagement and embodies our Group’s corporate mission of acting for an inclusive and sustainable society. Alongside Fondation pour la Recherche Médicale, CNP Assurances intends to support researchers in their fight against neurodegenerative diseases, the development of which cannot currently be slowed down through treatment.” says Agathe Sanson, Director of Stakeholder Dialogue, Communication and Sponsorship at CNP Assurances.
“Numerous studies suggest that Alzheimer’s disease is characterized not just by neurological dysfunction but also involves metabolic abnormalities. Improving these dysfunctions would constitute a new therapeutic pathway. The project that I am leading with my team aims to explore this hypothesis and could pave the way for new therapeutic perspectives to prevent or slow cognitive decline.
I would like to thank Fondation pour la Recherche Médicale for financing this project thanks to the support of CNP Assurances.” explains Erika Cecon, CNRS Research Officer at the Cochin Institute in Paris.
“With an ageing population, neurodegenerative diseases such as Alzheimer’s are becoming a major health issue. Despite recent advances, we do not have effective medicines to fight these diseases. FRM is investing substantially in Alzheimer’s research with a view to understanding the fundamental mechanisms of the onset and progression of the disease and identify new therapeutic avenues. Our far-reaching ambition calls for the commensurate investments. By working alongside us, CNP Assurances is helping to advance critical work for our health and our common future.” adds Valérie Lemarchandel, FRM Scientific Director.